Evaluation of a high-sensitivity assay for measurement of canine and feline serum cardiac troponin I

Rebecca Langhorn; Jakob Willesen; Inge Tarnow; Mads Kjelgaard-Hansen

doi:10.1111/vcp.12085

Evaluation of a high-sensitivity assay for measurement of canine and feline serum cardiac troponin I

Rebecca Langhorn, Jakob Willesen, Inge Tarnow, Mads Kjelgaard-Hansen

29 Citations (Scopus)

Abstract

Background: Cardiac troponins are established as the gold standard biomarkers for acute cardiac injury. As even small elevations of cardiac troponins have prognostic relevance in people, it is important to investigate the performance of sensitive assays for use in veterinary medicine. Objectives: The aim of this study was to evaluate analytical and overlap performance of a high-sensitivity cardiac troponin I (cTnI) assay, the ADVIA Centaur CP TnI-Ultra assay, in dogs and cats. Methods: Serum samples from dogs and cats with cardiac disease or arrhythmias, along with samples of purified canine free cTnI and complexed cTnI, T, and C (cTnI-T-C) were used in the assay validation study. Intra- and inter-assay variation, linearity under dilution, spike-and-recovery analysis, and detection limit were investigated to assess analytical performance. Overlap performance was evaluated based on the ability of the assay to discriminate between healthy animals and animals with cardiac disease or arrhythmias. Results: Intra-assay variation of cTnI in canine and feline serum ranged from 3.9 to 6.4% and from 4.0 to 4.8%, respectively. Inter-assay variation ranged from 2.7 to 4.7% and from 4.0 to 7.8%, respectively. The assay demonstrated acceptable linearity under dilution within a clinically relevant range of cTnI concentrations. Spike-and-recovery analysis showed excessive recovery in the range 150.7%-242.0% for free cTnI and 121.1-196.3% for complexed cTnI-T-C, partly due to a matrix effect. Overlap performance was acceptable as animals with cardiac disease or arrhythmias (n = 45 dogs, n = 53 cats) had significantly higher cTnI concentrations than healthy controls (P < .0001). Conclusions: The results confirm the ADVIA Centaur CP TnI-Ultra assay as a valuable tool for assessing cTnI and thus myocardial injury in dogs and cats.

Original language	English
Journal	Veterinary Clinical Pathology
Volume	42
Issue number	4
Pages (from-to)	490-498
Number of pages	9
ISSN	0275-6382
DOIs	https://doi.org/10.1111/vcp.12085
Publication status	Published - Dec 2013

Access to Document

10.1111/vcp.12085

Cite this

@article{53cd7e4456174806bafba5d89caf72c6,

title = "Evaluation of a high-sensitivity assay for measurement of canine and feline serum cardiac troponin I",

abstract = "Background: Cardiac troponins are established as the gold standard biomarkers for acute cardiac injury. As even small elevations of cardiac troponins have prognostic relevance in people, it is important to investigate the performance of sensitive assays for use in veterinary medicine. Objectives: The aim of this study was to evaluate analytical and overlap performance of a high-sensitivity cardiac troponin I (cTnI) assay, the ADVIA Centaur CP TnI-Ultra assay, in dogs and cats. Methods: Serum samples from dogs and cats with cardiac disease or arrhythmias, along with samples of purified canine free cTnI and complexed cTnI, T, and C (cTnI-T-C) were used in the assay validation study. Intra- and inter-assay variation, linearity under dilution, spike-and-recovery analysis, and detection limit were investigated to assess analytical performance. Overlap performance was evaluated based on the ability of the assay to discriminate between healthy animals and animals with cardiac disease or arrhythmias. Results: Intra-assay variation of cTnI in canine and feline serum ranged from 3.9 to 6.4% and from 4.0 to 4.8%, respectively. Inter-assay variation ranged from 2.7 to 4.7% and from 4.0 to 7.8%, respectively. The assay demonstrated acceptable linearity under dilution within a clinically relevant range of cTnI concentrations. Spike-and-recovery analysis showed excessive recovery in the range 150.7%-242.0% for free cTnI and 121.1-196.3% for complexed cTnI-T-C, partly due to a matrix effect. Overlap performance was acceptable as animals with cardiac disease or arrhythmias (n = 45 dogs, n = 53 cats) had significantly higher cTnI concentrations than healthy controls (P < .0001). Conclusions: The results confirm the ADVIA Centaur CP TnI-Ultra assay as a valuable tool for assessing cTnI and thus myocardial injury in dogs and cats.",

author = "Rebecca Langhorn and Jakob Willesen and Inge Tarnow and Mads Kjelgaard-Hansen",

note = "{\textcopyright} 2013 American Society for Veterinary Clinical Pathology.",

year = "2013",

month = dec,

doi = "10.1111/vcp.12085",

language = "English",

volume = "42",

pages = "490--498",

journal = "Veterinary Clinical Pathology",

issn = "0275-6382",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Evaluation of a high-sensitivity assay for measurement of canine and feline serum cardiac troponin I

AU - Langhorn, Rebecca

AU - Willesen, Jakob

AU - Tarnow, Inge

AU - Kjelgaard-Hansen, Mads

PY - 2013/12

Y1 - 2013/12

N2 - Background: Cardiac troponins are established as the gold standard biomarkers for acute cardiac injury. As even small elevations of cardiac troponins have prognostic relevance in people, it is important to investigate the performance of sensitive assays for use in veterinary medicine. Objectives: The aim of this study was to evaluate analytical and overlap performance of a high-sensitivity cardiac troponin I (cTnI) assay, the ADVIA Centaur CP TnI-Ultra assay, in dogs and cats. Methods: Serum samples from dogs and cats with cardiac disease or arrhythmias, along with samples of purified canine free cTnI and complexed cTnI, T, and C (cTnI-T-C) were used in the assay validation study. Intra- and inter-assay variation, linearity under dilution, spike-and-recovery analysis, and detection limit were investigated to assess analytical performance. Overlap performance was evaluated based on the ability of the assay to discriminate between healthy animals and animals with cardiac disease or arrhythmias. Results: Intra-assay variation of cTnI in canine and feline serum ranged from 3.9 to 6.4% and from 4.0 to 4.8%, respectively. Inter-assay variation ranged from 2.7 to 4.7% and from 4.0 to 7.8%, respectively. The assay demonstrated acceptable linearity under dilution within a clinically relevant range of cTnI concentrations. Spike-and-recovery analysis showed excessive recovery in the range 150.7%-242.0% for free cTnI and 121.1-196.3% for complexed cTnI-T-C, partly due to a matrix effect. Overlap performance was acceptable as animals with cardiac disease or arrhythmias (n = 45 dogs, n = 53 cats) had significantly higher cTnI concentrations than healthy controls (P < .0001). Conclusions: The results confirm the ADVIA Centaur CP TnI-Ultra assay as a valuable tool for assessing cTnI and thus myocardial injury in dogs and cats.

AB - Background: Cardiac troponins are established as the gold standard biomarkers for acute cardiac injury. As even small elevations of cardiac troponins have prognostic relevance in people, it is important to investigate the performance of sensitive assays for use in veterinary medicine. Objectives: The aim of this study was to evaluate analytical and overlap performance of a high-sensitivity cardiac troponin I (cTnI) assay, the ADVIA Centaur CP TnI-Ultra assay, in dogs and cats. Methods: Serum samples from dogs and cats with cardiac disease or arrhythmias, along with samples of purified canine free cTnI and complexed cTnI, T, and C (cTnI-T-C) were used in the assay validation study. Intra- and inter-assay variation, linearity under dilution, spike-and-recovery analysis, and detection limit were investigated to assess analytical performance. Overlap performance was evaluated based on the ability of the assay to discriminate between healthy animals and animals with cardiac disease or arrhythmias. Results: Intra-assay variation of cTnI in canine and feline serum ranged from 3.9 to 6.4% and from 4.0 to 4.8%, respectively. Inter-assay variation ranged from 2.7 to 4.7% and from 4.0 to 7.8%, respectively. The assay demonstrated acceptable linearity under dilution within a clinically relevant range of cTnI concentrations. Spike-and-recovery analysis showed excessive recovery in the range 150.7%-242.0% for free cTnI and 121.1-196.3% for complexed cTnI-T-C, partly due to a matrix effect. Overlap performance was acceptable as animals with cardiac disease or arrhythmias (n = 45 dogs, n = 53 cats) had significantly higher cTnI concentrations than healthy controls (P < .0001). Conclusions: The results confirm the ADVIA Centaur CP TnI-Ultra assay as a valuable tool for assessing cTnI and thus myocardial injury in dogs and cats.

U2 - 10.1111/vcp.12085

DO - 10.1111/vcp.12085

M3 - Journal article

C2 - 24131244

SN - 0275-6382

VL - 42

SP - 490

EP - 498

JO - Veterinary Clinical Pathology

JF - Veterinary Clinical Pathology

IS - 4

ER -

Evaluation of a high-sensitivity assay for measurement of canine and feline serum cardiac troponin I

Abstract

Access to Document

Fingerprint

Cite this